Cancer Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-10-20 ms1000001788822123 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：结直肠癌
经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。

49 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2025-03-12 ms4000001537645275 来自山西省

审稿速度:1.0
偏重的研究方向：肿瘤
经验分享：2024.11.27 Cancer Science投稿
2024.12.23 转投Cancer Medicine
2025.1.7 Under Review
2025.1.29 Major Revision
2025.2.21一审返修提交
2025.2.24Pending Recommendation
2025.2.27Under Review
后续在等待

25 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2025-05-17 147e4799m34暂无昵称来自浙江省

审稿速度:2.0
偏重的研究方向：免疫;肿瘤
经验分享：需要三遍wb，还那么慢，服了

8 0

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2020-04-26 木子孑孑

大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表:
2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。

wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。

204 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-07-07 ziecoe 来自重庆

审稿速度:2.0 | 投稿命中率:50.0
经验分享：27-Sep-2023 投稿， Undergoing initial checking
03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking
06-Oct-2023 Pending Editor Assignment
13-Oct-2023 Under Review
05-Dec-2023 Pending Recommendation
08-Dec-2023 Major Revision
26-Dec-2023 一审修回，退回，改格式，当天投回，
27-Dec-2023 Undergoing initial checking
28-Dec-2023 Pending Recommendation
17-Jan-2024 Under Review
08-Feb-2024 Pending Recommendation
27-Feb-2024 Under Review
13-Apr-2024 Major Revision
15-Apr-2024 二审修回，Undergoing initial checking
17-Apr-2024 Pending Recommendation
08-May-2024 Under Review
10-May-2024 Pending Recommendation
25-May-2024 Pending Decision
28-May-2024 Accept

114 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2025-03-13 120fdecem61暂无昵称来自江苏省

审稿速度:12.0 | 投稿命中率:25.0
经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!

15 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-03-29 ms5000001900218307 来自北京

之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历：
25-Nov-2023 投稿
26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修）
14-Mar-2024 修回（由于工作还有其他原因17天才修回）
16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题）
17-Mar-2024 第2天修回，修回第2天就显示pending decision
28-Mar-2024 Accept
这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩

179 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-03-22 零零一来自广西

可以聊聊，周期也就两三个月

63 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-07-12 ms1000001009157638 来自天津

偏重的研究方向：结直肠癌;临床
经验分享：3月21号投的，到现在还没一审结束，绝了

134 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2231920, encodeId=d411223192074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：结直肠癌 经验分享：7月25号投的，到现在还没一审结束，前前后后催了好几次了，还是没信，真是急死人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822123, createdTime=Sun Oct 20 18:35:41 CST 2024, time=2024-10-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2255764, encodeId=a5912255e64de, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：2024.11.27 Cancer Science投稿 2024.12.23 转投Cancer Medicine 2025.1.7 Under Review 2025.1.29 Major Revision 2025.2.21一审返修提交 2025.2.24Pending Recommendation 2025.2.27Under Review 后续在等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d32c9636955, createdName=ms4000001537645275, createdTime=Wed Mar 12 17:13:14 CST 2025, time=2025-03-12, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2265494, encodeId=1ebb2265494e9, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：需要三遍wb，还那么慢，服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25915252522, createdName=147e4799m34暂无昵称, createdTime=Sat May 17 21:20:33 CST 2025, time=2025-05-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=589719, encodeId=5a05589e1940, content=大佬，请问接收后多久交版面费和proof？wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, beContent=wuyi1000 2019-10-13 00:00:00 发表: 2019-07-01 Submitted/Undergoing initial checking 2019-07-04 Under Review 2019-07-25 Pending Decision 2019-07-25 Major Revision 2019-08-08 Resubmitted/Undergoing initial checking 2019-08-08 Pending Decision 2019-08-12 Under Review 2019-08-29 Pending Decision 2019-08-30 Minor Revision 2019-09-01 Resubmitted/Undergoing initial checking 2019-09-03 Pending Decision 2019-09-10 Under Review 2019-09-27 Pending Decision 2019-10-08 Accept 请问各位大佬，接收后多久交版面费和proof。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ah6TsnTicIedAahqYyu4Vaz8AYx4BFqtrbafZUbkeYavADIrrBAGT3u6tn2YT6YicbtgnxwcT9sF0mCUKNcTKSiaw/132, createdBy=912e5276906, createdName=木子孑孑, createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213669, encodeId=e63022136697d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：27-Sep-2023 投稿， Undergoing initial checking 03-Oct-2023 退回，改格式，当天投回，变成Undergoing initial checking 06-Oct-2023 Pending Editor Assignment 13-Oct-2023 Under Review 05-Dec-2023 Pending Recommendation 08-Dec-2023 Major Revision 26-Dec-2023 一审修回，退回，改格式，当天投回， 27-Dec-2023 Undergoing initial checking 28-Dec-2023 Pending Recommendation 17-Jan-2024 Under Review 08-Feb-2024 Pending Recommendation 27-Feb-2024 Under Review 13-Apr-2024 Major Revision 15-Apr-2024 二审修回，Undergoing initial checking 17-Apr-2024 Pending Recommendation 08-May-2024 Under Review 10-May-2024 Pending Recommendation 25-May-2024 Pending Decision 28-May-2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8abb105234, createdName=ziecoe, createdTime=Sun Jul 07 00:08:26 CST 2024, time=2024-07-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2255826, encodeId=5bfd225582641, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：非常差的体验，转投到这个期刊的，投完发邮件说接收后要4000+刀，吓坏了，一个小杂志要这么多。审了2个月无任何意见拒稿。之前生信火起来很多人就往这个上面灌，就对这个期刊印象很差，不给意见拒稿，也符合我对这种不专业期刊的刻板印象。说实话拒稿也让我松一口气，把版面费交到这种期刊挺不值的。这个期刊今年2区，明年必掉3,4区。后来又投了老牌中科院top，顺利接收。感谢cancer medicine 不收之恩!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03292220942, createdName=120fdecem61暂无昵称, createdTime=Thu Mar 13 01:37:15 CST 2025, time=2025-03-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196078, encodeId=b48721960e8a3, content=之前投稿前还有等待过程中看了很多小伙伴的经验，对我的帮助很大，现在我也来分享一下我的投稿经历： 25-Nov-2023 投稿 26-Feb-2024 Major Revision（一共3个审稿人，第1个审稿人非常仔细，提了很多的问题，另外2个审稿人提的问题比较少，总体来说都很专业，而且没有故意为难，编辑部给了大修） 14-Mar-2024 修回（由于工作还有其他原因17天才修回） 16-Mar-2024 Minor Revision （大修回去2天就返回了小修意见，副编辑提了两点小问题） 17-Mar-2024 第2天修回，修回第2天就显示pending decision 28-Mar-2024 Accept 这次投稿过程非常顺利，中间提交返修稿的时候由于邮箱的问题导致提交不了，发邮件给编辑部很快就帮忙解决了，而且态度很好，感恩, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73845585388, createdName=ms5000001900218307, createdTime=Fri Mar 29 14:56:05 CST 2024, time=2024-03-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194624, encodeId=31c52194624ab, content=可以聊聊，周期也就两三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Fri Mar 22 09:21:58 CST 2024, time=2024-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2214554, encodeId=7e902214554e6, content=偏重的研究方向：结直肠癌;临床 经验分享：3月21号投的，到现在还没一审结束，绝了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e8f8631531, createdName=ms1000001009157638, createdTime=Fri Jul 12 09:27:34 CST 2024, time=2024-07-12, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2224111, encodeId=1a6e2224111e6, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：今天年3月初 submitted 5.8under review 5.20 minor revision 2个reviewer各3条意见 5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。 reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:30:05 CST 2024, time=2024-09-04, status=1, ipAttribution=上海)]

2024-09-04 ms1000001788820000 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：今天年3月初 submitted
5.8under review
5.20 minor revision 2个reviewer各3条意见
5.28 修回2天后accept杂志慢的阶段主要在处理和送审阶段。
reviewer给的意见都比较积极，因此revision以后应该没送外审，直接编辑部决定了，总体还可以。

60 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务